Open Access

Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis

  • Authors:
    • Houwei Zhu
    • Yanqing Qu
  • View Affiliations

  • Published online on: December 17, 2019     https://doi.org/10.3892/ol.2019.11223
  • Pages: 1241-1246
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Expression levels of autophagy‑related genes ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis were investigated. The expression levels of ARHI and Beclin1 proteins in 80 cases of thyroid cancer and adjacent tissues were detected by western blot analysis. According to the expression levels of ARHI and Beclin1, low‑ and high‑expression groups were determined and the relationship of the expression levels with the pathological parameters and prognosis in thyroid cancer was compared between the two groups. The correlation between the ARHI and Beclin1 protein expression level was analyzed by Pearson's correlation analysis. The levels of ARHI and Beclin1 proteins in thyroid cancer tissues were significantly lower than those in adjacent tissues (P<0.05). There was a significant difference in the expression levels of ARHI and Beclin1 in terms of pathological stage and differentiation degree of cancer tissues (P<0.001); however, there was no significant difference in the expression levels of ARHI and Beclin1 for different types of cancer tissues (P>0 05). There was a positive correlation between the expression levels of Beclin1 and ARHI (r=0.5187, P<0.001). The 3‑year survival rates of patients with low‑expression level of ARHI and Beclin1 proteins were significantly lower than those of patients with high expression (P<0.05). In conclusion, the expression levels of Beclin1 and ARHI were low in thyroid cancer, and were significantly associated with the pathological stage, differentiation degree and prognosis in thyroid cancer. Beclin1 and ARHI can be used as predictors for the development and prognosis of thyroid cancer.
View Figures
View References

Related Articles

Journal Cover

February-2020
Volume 19 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu H and Zhu H: Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis. Oncol Lett 19: 1241-1246, 2020
APA
Zhu, H., & Zhu, H. (2020). Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis. Oncology Letters, 19, 1241-1246. https://doi.org/10.3892/ol.2019.11223
MLA
Zhu, H., Qu, Y."Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis". Oncology Letters 19.2 (2020): 1241-1246.
Chicago
Zhu, H., Qu, Y."Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis". Oncology Letters 19, no. 2 (2020): 1241-1246. https://doi.org/10.3892/ol.2019.11223